Artivion (NYSE:AORT) Posts Earnings Results, Beats Expectations By $0.14 EPS

Artivion (NYSE:AORT) announced its quarterly earnings data on Thursday. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.14, FiscalAI reports. The business had revenue of $123.79 million for the quarter, compared to analyst estimates of $120.97 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%.

Here are the key takeaways from Artivion’s conference call:

• Third-quarter revenue grew 9% year over year in constant currency, led by 12% growth in stent grafts and 13% growth in On-X valves. Management said On-X supply has improved after manufacturing investments, while acknowledging that adjusted EBITDA fell 8% and gross margin declined.
• Artivion narrowed its 2026 outlook to 8%–10% adjusted constant-currency revenue growth and $93 million–$98 million of adjusted EBITDA. Management cited a Q4 currency headwind and an expected reversal of unusually strong preservation-services revenue; it also forecast PerClot’s departure to reduce 2027 revenue growth by about 2 percentage points and EBITDA growth by 4 points.
• AMDS implants increased following U.S. PMA approval, but starter-set sales remain slow because hospitals face administrative hurdles around the roughly $100,000 upfront purchase. Management said it is working to ease those barriers, but expects account adoption to take time.
• NEXUS preparations are progressing toward a planned U.S. launch on January 1, 2027, with surgeon interest, training, inventory-building, and sales-team expansion underway. Management expects sales to ramp gradually through 2027 and anticipates the combined business will be EBITDA-neutral for the year.
• The ARTIZEN trial for the Arcevo LSA platform has enrolled 56 patients, with enrollment completion expected in mid-2027. Management expects to present initial results from the first 30 patients and, if the trial succeeds, anticipates FDA approval in 2029.

Artivion Stock Performance

AORT stock traded down $5.09 during midday trading on Friday, reaching $20.23. 3,246,962 shares of the company were exchanged, compared to its average volume of 486,118. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.47 and a quick ratio of 2.51. The business has a 50-day moving average price of $23.55 and a two-hundred day moving average price of $28.98. Artivion has a one year low of $19.16 and a one year high of $48.25. The firm has a market capitalization of $986.66 million, a price-to-earnings ratio of 43.67 and a beta of 1.31.

Analyst Ratings Changes

Several equities research analysts have commented on AORT shares. Needham & Company LLC reissued a “buy” rating and set a $44.00 price target on shares of Artivion in a research report on Monday, July 20th. Citizens Jmp decreased their price objective on Artivion from $48.00 to $42.00 and set a “market outperform” rating for the company in a report on Friday. Citigroup reaffirmed a “market outperform” rating on shares of Artivion in a research report on Tuesday, July 21st. Wall Street Zen lowered Artivion from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Weiss Ratings cut Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $40.57.

Artivion News Summary

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q3 revenue rose 9% year over year to $123.8 million, exceeding analysts’ estimates of about $121 million. The company also reported non-GAAP EPS of $0.08, above a consensus estimate of a $0.06 loss cited in one report. Artivion Q3 results
• Positive Sentiment: Artivion forecast 2026 revenue of $484 million to $492 million and said it is preparing to launch its NEXUS product in January 2027, offering potential future growth catalysts. Revenue outlook and NEXUS launch
• Neutral Sentiment: Citizens JMP lowered its price target to $42 from $48 but maintained a Market Outperform rating; the revised target still implies substantial upside from the cited share price. Citizens JMP recommendations
• Negative Sentiment: Canaccord also cut its target, to $30, adding to concerns about analysts’ reassessment of the stock’s outlook. Canaccord price-target change
• Negative Sentiment: Despite revenue growth, Artivion posted a $7.9 million GAAP net loss, and adjusted EBITDA fell 8% to $22.5 million. Zacks also reported that the $0.08 quarterly EPS missed its $0.11 estimate, highlighting that earnings expectations vary by source and may weigh on sentiment. Zacks earnings analysis

Insider Activity

In related news, CEO James P. Mackin sold 70,000 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total value of $2,026,500.00. Following the transaction, the chief executive officer owned 877,275 shares in the company, valued at approximately $25,397,111.25. This represents a 7.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jean F. Holloway sold 977 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total value of $27,834.73. Following the transaction, the senior vice president owned 184,118 shares in the company, valued at approximately $5,245,521.82. This trade represents a 0.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 90,460 shares of company stock valued at $2,557,366 over the last ninety days. 6.30% of the stock is currently owned by company insiders.

About Artivion

Artivion, Inc (NYSE: AORT) is a medical device and biotechnology company focused on developing and commercializing products used in cardiac and vascular surgery. Its portfolio includes implantable devices, surgical sealants, and human tissue products designed to treat diseases of the heart, aorta, and peripheral blood vessels.

The company’s products include On-X mechanical heart valves, aortic and vascular grafts, BioGlue surgical adhesive, and stent graft systems for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in reconstructive procedures.

Artivion was formerly known as CryoLife, a company founded in 1984, and adopted the Artivion name in 2021 to reflect its broader focus on aortic and cardiac care.